Genelux Investor Presentation Deck
Phase 1b: Anti-tumor Activity as Monotherapy Leading into Combination
Patient Background &
Study Treatment
Platinum-resistant/
refractory ovarian cancer
Heavily pre-treated
patients with
documented
progressive disease at
baseline
●
Single cycle of high &
condensed bolus
infusions (intraperitoneal
delivery) on 2
consecutive days;
total dose: 6x10⁹ pfu
GENELUX
Pod
die g
Olvi-Vec Monotherapy (11 patients)
Tolerability:
No Dose Limiting Toxicity (DLT)
No Maximum Tolerated Dose (MTD)
No Grade 4 Adverse Events (AE)
●
●
●
Antitumor activity:
Clinical Benefit Rate: 73% (8/11)
4/11 patients had >2x PFS relative to immediate prior
chemotherapy
●
●
Translational Evidence:
Activation of tumor-specific T cell response detected in blood
Documented immune activation in tumor microenvironment
●
●
with significant influx of TILS
Favorable immune-related genetic signatures
Manyam et al., Gynecologic Oncology 163 (2021) 481 - 489
11View entire presentation